Maurizio Iacobone1, Bruno Carnaille2, F Fausto Palazzo3, Menno Vriens4. 1. Endocrine Surgery Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Via Giustiniani 2, 35128, Padova, Italy. maurizio.iacobone@unipd.it. 2. Department of Endocrine Surgery, Université de Lille, Lille, France. 3. Department of Endocrine and Thyroid Surgery, Hammersmith Hospital and Imperial College, London, UK. 4. Department of Surgical Oncology and Endocrine Surgery, Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands.
Abstract
BACKGROUND: Hereditary hyperparathyroidism has been reported to occur in 5-10 % of cases of primary hyperparathyroidism in the context of multiple endocrine neoplasia (MEN) types 1, 2A and 4; hyperparathyroidism-jaw tumour (HPT-JT); familial isolated hyperparathyroidism (FIHPT); familial hypocalciuric hypercalcaemia (FHH); neonatal severe hyperparathyroidism (NSHPT) and autosomal dominant moderate hyperparathyroidism (ADMH). This paper aims to review the controversies in the main genetic, clinical and pathological features and surgical management of hereditary hyperparathyroidism. METHODS: A peer review literature analysis on hereditary hyperparathyroidism was carried out and analyzed in an evidence-based perspective. Results were discussed at the 2015 Workshop of the European Society of Endocrine Surgeons devoted to hyperparathyroidism due to multiple gland disease. RESULTS: Literature reports scarcity of prospective randomized studies; thus, a low level of evidence may be achieved. CONCLUSIONS: Hereditary hyperparathyroidism typically presents at an earlier age than the sporadic variants. Gene penetrance and expressivity varies. Parathyroid multiple gland involvement is common, but in some variants, it may occur metachronously often with long disease-free intervals, simulating a single-gland involvement. Bilateral neck exploration with subtotal parathyroidectomy or total parathyroidectomy + autotransplantation should be performed, especially in MEN 1, in order to decrease the persistent and recurrent hyperparathyroidism rates; in some variants (MEN 2A, HPT-JT), limited parathyroidectomy can achieve long-term normocalcemia. In FHH, surgery is contraindicated; in NSHPT, urgent total parathyroidectomy is required. In FIHPT, MEN 4 and ADMH, a tailored case-specific approach is recommended.
BACKGROUND:Hereditary hyperparathyroidism has been reported to occur in 5-10 % of cases of primary hyperparathyroidism in the context of multiple endocrine neoplasia (MEN) types 1, 2A and 4; hyperparathyroidism-jaw tumour (HPT-JT); familial isolated hyperparathyroidism (FIHPT); familial hypocalciuric hypercalcaemia (FHH); neonatal severe hyperparathyroidism (NSHPT) and autosomal dominant moderate hyperparathyroidism (ADMH). This paper aims to review the controversies in the main genetic, clinical and pathological features and surgical management of hereditary hyperparathyroidism. METHODS: A peer review literature analysis on hereditary hyperparathyroidism was carried out and analyzed in an evidence-based perspective. Results were discussed at the 2015 Workshop of the European Society of Endocrine Surgeons devoted to hyperparathyroidism due to multiple gland disease. RESULTS: Literature reports scarcity of prospective randomized studies; thus, a low level of evidence may be achieved. CONCLUSIONS:Hereditary hyperparathyroidism typically presents at an earlier age than the sporadic variants. Gene penetrance and expressivity varies. Parathyroid multiple gland involvement is common, but in some variants, it may occur metachronously often with long disease-free intervals, simulating a single-gland involvement. Bilateral neck exploration with subtotal parathyroidectomy or total parathyroidectomy + autotransplantation should be performed, especially in MEN 1, in order to decrease the persistent and recurrent hyperparathyroidism rates; in some variants (MEN 2A, HPT-JT), limited parathyroidectomy can achieve long-term normocalcemia. In FHH, surgery is contraindicated; in NSHPT, urgent total parathyroidectomy is required. In FIHPT, MEN 4 and ADMH, a tailored case-specific approach is recommended.
Entities:
Keywords:
ADMH; FHH; FIHPT; Familial primary hyperparathyroidism; HPT-JT; Hereditary primary hyperparathyroidism; MEN 1; MEN 2; MEN 4; Multiple gland disease; NSHPT; Parathyroidectomy
Authors: Francesco Tonelli; Tommaso Marcucci; Francesco Giudici; Alberto Falchetti; Maria Luisa Brandi Journal: Endocr J Date: 2009-10-02 Impact factor: 2.349
Authors: Terry C Lairmore; Cara M Govednik; Courtney E Quinn; Benjamin R Sigmond; Cortney Y Lee; Daniel C Jupiter Journal: Surgery Date: 2014-09-26 Impact factor: 3.982
Authors: Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack Journal: Thyroid Date: 2015-06 Impact factor: 6.568
Authors: M G Chiofalo; A Sparaneo; M Chetta; R Franco; F Baorda; L Cinque; M Granatiero; L D'Agruma; L Pezzullo; A Scillitani; V Guarnieri Journal: Cell Oncol (Dordr) Date: 2014-08-12 Impact factor: 6.730
Authors: Laura A Lambert; Suzanne E Shapiro; Jeffrey E Lee; Nancy D Perrier; Mylene Truong; Michael J Wallace; Ana O Hoff; Robert F Gagel; Douglas B Evans Journal: Arch Surg Date: 2005-04
Authors: W S Wassif; C F Moniz; E Friedman; S Wong; G Weber; M Nordenskjöld; T J Peters; C Larsson Journal: J Clin Endocrinol Metab Date: 1993-12 Impact factor: 5.958
Authors: Mustapha El Lakis; Pavel Nockel; Apostolos Gaitanidis; Bin Guan; Sunita Agarwal; James Welch; William F Simonds; Lee Weinstein; Stephen Marx; Naris Nilubol; Dhaval Patel; Roxanne Merkel; Amit Tirosh; Electron Kebebew Journal: J Am Coll Surg Date: 2018-03-02 Impact factor: 6.113
Authors: Bin Guan; James M Welch; Julie C Sapp; Hua Ling; Yulong Li; Jennifer J Johnston; Electron Kebebew; Leslie G Biesecker; William F Simonds; Stephen J Marx; Sunita K Agarwal Journal: Am J Hum Genet Date: 2016-10-13 Impact factor: 11.025
Authors: Serena Grimaldi; Jacques Young; Peter Kamenicky; Dana Hartl; Marie Terroir; Sophie Leboulleux; Amandine Berdelou; Julien Hadoux; Segolene Hescot; Hervé Remy; Eric Baudin; Martin Schlumberger; Désirée Deandreis Journal: Eur J Nucl Med Mol Imaging Date: 2018-04-22 Impact factor: 9.236
Authors: T Weber; C Dotzenrath; H Dralle; B Niederle; P Riss; K Holzer; J Kußmann; A Trupka; T Negele; R Kaderli; E Karakas; F Weber; N Rayes; A Zielke; M Hermann; C Wicke; R Ladurner; C Vorländer; J Waldmann; O Heizmann; S Wächter; S Schopf; W Timmermann; D K Bartsch; R Schmidmaier; M Luster; K W Schmid; M Ketteler; C Dierks; P Schabram; T Steinmüller; K Lorenz Journal: Langenbecks Arch Surg Date: 2021-04-21 Impact factor: 3.445
Authors: Shafaq Khairi; Jenae Osborne; Michelle F Jacobs; Gregory T Clines; Barbra S Miller; David T Hughes; Tobias Else Journal: Horm Cancer Date: 2020-08-05 Impact factor: 3.869
Authors: Robert D Rampp; Edna E Mancilla; N Scott Adzick; Michael A Levine; Rachel R Kelz; Douglas L Fraker; Pallavi Iyer; Brenessa M Lindeman; Vicente A Mejia; Herbert Chen; Heather Wachtel Journal: World J Surg Date: 2020-05 Impact factor: 3.352